Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation

American Journal of Transplantation

Volumn 9, Issue 3, 2009, Pages 610-613

  Dharancy, S ^a,b   Iannelli, A ^c   Hulin, A ^d   Declerck, N ^a   Schneck, A S ^c   Mathurin, P ^a,b   Boleslawski, E ^a   Gugenheim, J ^c   Pruvot, F R ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

Chronic renal dysfunction; Liver transplantation; Mycophenolate mofetyl

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; TACROLIMUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; METABOLIC DISORDER; MONOTHERAPY; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; CALCINEURIN; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 60649106991     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02529.x     Document Type: Article

References (19)

1. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003 349 : 931 940.
2. Platz KP, Mueller AR, Blumhardt G et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994 58 : 170 178.
3. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005 11 : 750 759.
4. Pfitzmann R, Klupp J, Langrehr JM et al. Mycophenolatemofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients. Transplantation 2003 76 : 130 136.
5. Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001 7 : 442 450.
6. Creput C, Blandin F, Deroure B et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 2007 13 : 1004 1010.
7. Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 2005 80 : 18 25.
8. Barkmann A, Nashan B, Schmidt HH et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000 69 : 1886 1890.
9. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experience. Liver Transpl 2004 10 : 1189 1194.
10. Herrero JI, Quiroga J, Sangro B et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999 5 : 414 420.
11. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004 4 : 1650 1655.
12. Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 2005 37 : 2614 2615.
13. Raimondo ML, Dagher L, Papatheodoridis GV et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003 75 : 186 190.
14. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001 357 : 587 591.
15. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001 357 : 609 610.
16. Orlando G, Baiocchi L, Cardillo A et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007 13 : 46 54.
17. Schmeding M, Neumann UP, Neuhaus R, Neuhaus P. Mycophenolate mofetil in liver transplantation - Is monotherapy safe Clin Transplant 2006 20 (Suppl 17 75 79.
18. Berlakovich GA, Imhof M, Karner-Hanusch J et al. The importance of the effect of underlying disease on rejection outcomes following orthotopic liver transplantation. Transplantation 1996 61 : 554 560.
19. Hazzan M, Labalette M, Copin MC et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial. J Am Soc Nephrol 2005 16 : 2509 2516.